Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) generates frequent news related to corporate strategy, asset sales, stockholder actions, and exchange listing matters. Historically focused on scientifically created and clinically proven eyecare, wound care, and skin care products, NovaBay’s recent headlines have centered on the Avenova eyecare brand and significant changes to its business structure.
News coverage for NovaBay has included announcements about the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC. The company has reported that this asset sale represented substantially all of its assets and required stockholder approval at special meetings. These developments are important for understanding how NovaBay has monetized its historical operating business and redirected value to stockholders.
Another major category of news involves stockholder meetings and proposals. NovaBay has issued multiple press releases about special meetings and reconvened meetings where stockholders were asked to vote on the sale of the Avenova business and on a Plan of Complete Liquidation and Dissolution. Later communications describe stockholder approval of the Dissolution proposal and the Board’s decision to evaluate alternative strategic options, including mergers, reverse mergers, strategic partnerships, and licensing transactions.
More recent items highlight an investment transaction involving Series D and Series E non-voting convertible preferred stock, the declaration of a one-time special cash dividend, and NovaBay’s disclosure that it regained compliance with NYSE American continued listing standards. Investors following NBY news can track updates on these capital structure changes, special dividend mechanics, and any future post-investment transaction the company may pursue. This news page offers a consolidated view of NovaBay’s press releases and related coverage, providing context on how its strategic direction and corporate actions are evolving over time.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will disclose its financial results for the year ending December 31, 2020, after market close on March 25, 2021. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results with investors. Participants can pre-register for the call to receive a unique PIN for immediate access, or join live by dialing designated phone numbers. A replay will be available until April 15, 2021. More details can be found on NovaBay's investor website.
NovaBay Pharmaceuticals (NYSE American: NBY) will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference from March 15-17, 2021. The company focuses on commercializing Avenova® for eye care and CelleRx® Clinical Reset™ for beauty. Investors can arrange meetings through Roth Capital Partners or LHA Investor Relations. Additionally, the corporate presentation is available on the company's website. NovaBay specializes in non-antibiotic anti-infective products, including the NEUTROX® family and AGANOCIDE® compounds.
NovaBay Pharmaceuticals (NYSE American: NBY) provided a Letter to Stockholders detailing its growth strategy for 2021, focusing on expanding sales of Avenova and CelleRx Clinical Reset. Avenova will debut in 3,000 CVS stores, enhancing consumer access. The company aims to build on its strong market position, targeting the large ophthalmic and skincare markets. Independent lab results confirm Avenova's effectiveness against SARS-CoV-2. NovaBay improved its financial standing, reducing cash burn and eliminating debt to support growth initiatives.
NovaBay Pharmaceuticals (NBY) announced that its hypochlorous acid solution has gained EPA approval for killing SARS-CoV-2, the virus causing COVID-19. This follows independent lab tests proving its efficacy on hard surfaces, validating the product for consumer use on items like eyeglasses and cell phones. CEO Justin Hall emphasized the significance of this approval, highlighting NovaBay's innovation in stabilizing hypochlorous acid without toxic chemicals. The company aims to address unmet therapeutic needs in the topical anti-infective market.